MarketAxess Announces Monthly Volume Statistics for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
MarketAxess Announces Monthly Volume Statistics for September 2013

NEW YORK, Oct. 2, 2013 (GLOBE NEWSWIRE) -- MarketAxess Holdings Inc. (Nasdaq: MKTX ), the operator of a leading electronic trading platform for fixed-income securities, and the provider of market data and post-trade services for the global fixed-income markets, today announced total monthly trading volume for September 2013 of $65.6 billion, consisting of $44.0 billion in U.S. high-grade volume, $15.7 billion in other credit volume, and $5.9 billion in liquid products volume. This data can be accessed on MarketAxess' website at www.marketaxess.com .

Monthly volume updates are posted in the Investor Relations section of the website on or before the tenth business day of each month. The data provide current month and historical volume totals on a monthly, quarterly and annual basis.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements, including statements about the outlook and prospects for Company and industry growth, as well as statements about the Company's future financial and operating performance. These and other statements that relate to future results and events are based on MarketAxess' current expectations. Actual results in future periods may differ materially from those currently expected or desired because of a number of risks and uncertainties, including: the volatility of financial services markets generally; the level of trading volume transacted on the MarketAxess platform; the absolute level and direction of interest rates and the corresponding volatility in the corporate fixed-income market; the level and intensity of competition in the fixed-income electronic trading industry and the pricing pressures that may result; the variability of our growth rate; the rapidly evolving nature of the electronic financial services industry; our ability to introduce new fee plans and our clients' response; our exposure to risks resulting from non-performance by counterparties to transactions executed between our clients in which we act as an intermediary in matching back-to-back trades; our dependence on our broker-dealer clients; the loss of any of our significant institutional investor clients; our ability to develop new products and offerings and the market's acceptance of those products; the effect of rapid market or technological changes on us and the users of our technology; our ability to successfully maintain the integrity of our trading platform and our response to system failures, capacity constraints and business interruptions; our vulnerability to cyber security risks; our ability to protect our intellectual property rights or technology and defend against intellectual property infringement or other claims; our ability to enter into strategic alliances and to acquire other businesses and successfully integrate them with our business; our ability to comply with new laws, rules and regulations both domestically and internationally; our ability to maintain effective compliance and risk management methods; the strain of growth initiatives on management and other resources; our future capital needs and our ability to obtain capital when needed; limitations on our operating flexibility contained in our credit agreement; and other factors. The Company's actual results and financial condition may differ, perhaps materially, from the anticipated results and financial condition in any such forward-looking statements. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. More information about these and other factors affecting MarketAxess' business and prospects is contained in MarketAxess' periodic filings with the Securities and Exchange Commission and can be accessed at www.marketaxess.com.  ;

About MarketAxess

MarketAxess operates a leading electronic trading platform that enables fixed-income market participants to efficiently trade corporate bonds and other types of fixed-income instruments using MarketAxess' patented trading technology. Over 1,000 institutional investor and broker-dealer firms are active users of the MarketAxess trading platform, accessing global liquidity in U.S. high-grade corporate bonds, European bonds, high-yield and emerging markets bonds, agency bonds, asset-backed and preferred securities and credit default swaps. MarketAxess has submitted an application to the U.S. Commodity Futures Trading Commission to operate a swap execution facility. MarketAxess also offers a number of trading-related products and services, including: market data to assist clients with trading decisions; connectivity solutions that facilitate straight-through processing; technology services to optimize trading environments; and execution services for exchange-traded fund managers and other clients. Through its Xtrakter subsidiary, MarketAxess also offers a range of pre- and post-trade services, including trade matching, regulatory transaction reporting and market and reference data, across a range of fixed-income products.

MarketAxess maintains its headquarters in New York and has offices in London, Chicago, Salt Lake City, Hong Kong, Singapore and São Paulo. For more information, please visit www.marketaxess.com .

Investor Relations Contact: Tony DeLise MarketAxess Holdings Inc. +1-212-813-6017 Media Relations Contacts: Florencia Panizza MarketAxess Holdings Inc. +1-212-813-6029 William McBride William McBride & Associates +1-917-239-6726

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 35

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 26

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 23

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 32

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Kotak Mahindra Bank's Innovative Tech Strategies

Updated Category News Views 587

Kotak Mahindra Bank's Commitment to Digital Transformation Kotak Mahindra Bank is at the forefront of revolutionizing financial services through its innovative technology strategies. Their latest report dives deep into the bank's extensive tech activities, highlighting how it leverages digital transformation to enhance customer experience and streamline operations....

Continue Reading
Star Group, L.P. Reflects on Fiscal 2024 Performance Updates

Updated Category News Views 349

Star Group's Fiscal 2024 Insights and Performance Analysis As the fiscal year wraps up, Star Group, L.P. (NYSE: SGU), a respected home energy distributor, shares its financial performance that ended on September 30, 2024. Amidst the prevailing challenges in the energy market, the company continues its commitment to delivering quality services while adapting to market...

Continue Reading
Krystal Biotech Launches Clinical Trial for Eye Therapy KB801

Updated Category News Views 148

Krystal Biotech Begins Phase 1/2 Trial of KB801 Krystal Biotech, Inc. (NASDAQ: KRYS) has recently announced exciting developments in its ophthalmology pipeline with the initiation of a Phase 1/2 clinical trial for KB801, aimed at treating neurotrophic keratitis (NK). This 2:1 randomized, double-masked, multicenter, placebo-controlled study, named EMERALD-1, marks a...

Continue Reading
Key Updates on the Annual General Meeting of Ignitis Group

Updated Category News Views 163

Exciting Updates for the Ignitis Group Shareholders The retained earnings figure for AB “Ignitis grup?” has been amended for the upcoming Annual General Meeting. It now stands at EUR 320,319,368.41, following a revision made only to the English version of the document. This adjustment reflects the company’s commitment to transparency and accuracy in their financial...

Continue Reading
Transforming Connectivity: The Future of mmWave Sensors Growth

Updated Category News Views 104

The mmWave sensors market was set on a blistering growth path back in 2023, valued at around USD 0.25 billion. By the time you fast-forward to 2032, projections had it skyrocketing to USD 2.40 billion, boasting a staggering CAGR of 28.59% from 2024 through 2032. You'd think this kind of momentum would have traders buzzing—oh wait, they were, especially as the push for...

Continue Reading